Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

SARUPANC - A multicentric, single arm, phase II trial assessing the efficacy of suraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer

This study, called SARUPANC, is looking into a new treatment named Saruparib for people in the UK who have pancreatic cancer that has spread to other parts of the body. This particular study is for patients whose cancer has a specific genetic weakness, known as 'homologous repair-deficient' cancer. The main goal is to see how much the new drug can shrink tumours in these patients after 16 weeks of treatment. Researchers will also be checking other important things, like how long people live without their cancer getting worse, how long the treatment keeps the cancer under control, and how it affects their daily lives and well-being. It's a Phase II study, meaning it's aimed at finding out if this new drug is effective enough to move on to larger studies.

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Centre Leon Berard

Enrolment target

700

Start

23 Jan 2026

Pancreatic (PAAD)

What is this study about?

This study is called SARUPANC, and it's looking into a new medicine called Saruparib. It's for people in the UK who have pancreatic cancer that has spread to other parts of the body, which doctors call 'metastatic' cancer. Importantly, this study is only for those whose cancer has a specific genetic weakness. This weakness, called 'homologous repair-deficient,' means the cancer cells might be more sensitive to certain treatments, like Saruparib.

The main aim of this study is to see how well Saruparib works as a very first treatment for this specific type of advanced pancreatic cancer. They will be measuring this by seeing how many patients' tumours shrink noticeably or stop growing after 16 weeks of taking the medication. This will help doctors understand if Saruparib could be a good new option for some patients.

Beyond just looking at tumour shrinkage, the researchers will also be paying close attention to other important aspects. They want to know how long the benefits of the treatment last, how it affects patients' overall health and well-being, and what side effects might occur. All this information is crucial for understanding the full picture of how Saruparib might help patients in the future.

Key takeaways

This study is for a new drug, Saruparib, for advanced pancreatic cancer.
It's specifically for pancreatic cancer with a genetic weakness called 'homologous repair-deficient'.
The main goal is to see if the drug shrinks tumours after 16 weeks.
Researchers will also track side effects and how the treatment affects quality of life.
It's a Phase II study, meaning it's an earlier stage of testing to check effectiveness and safety.

Who may be eligible?

To join this study, you must be at least 18 years old – there's no upper age limit. Both men and women can take part.

To be considered, your pancreatic cancer must have spread to other parts of your body. Crucially, your cancer must also have a specific genetic feature known as 'homologous repair deficiency'. Your doctor will be able to tell if your cancer has this feature through special tests.

There will be other medical checks to make sure the study treatment is safe for you and that you meet all the necessary health requirements. Your doctor and the study team will go through all these details with you carefully to see if this study is suitable for your situation.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Has your pancreatic cancer spread to other parts of your body?
Has your doctor confirmed your cancer has the 'homologous repair-deficient' genetic feature?
Are you able to start a new treatment as a first option for your advanced cancer?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would be taking the study drug, Saruparib, as your main treatment. You would likely have regular visits to the clinic for medical check-ups, blood tests, and scans to see how you are responding to the treatment. These scans are done regularly to measure the cancer and see if it's shrinking or staying stable. You would also be asked to fill out questionnaires about your quality of life to understand how the treatment affects your daily well-being. The study would continue for as long as the treatment is helping you and is not causing serious side effects, or until your doctor advises otherwise.

Potential risks and benefits

Participating in this study might offer a potential benefit if Saruparib proves to be an effective treatment for your specific type of cancer. It could mean access to a new drug before it's widely available. However, like all medicines, Saruparib may have side effects, which could range from mild to serious. The study team will carefully monitor you for any side effects and provide support. Remember, you can choose to leave the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is 'homologous repair-deficient' pancreatic cancer?

This is a type of pancreatic cancer where the cancer cells have trouble repairing damaged DNA. This specific weakness might make these cancer cells more sensitive to certain treatments like the one being tested in this study.

What does a 'Phase II' study mean?

A Phase II study means this is one of the earlier stages of drug testing. It aims to see if a new treatment is effective, safe, and worth testing in a larger group of patients in future studies called Phase III.

What is 'Objective Response Rate at Week 16'?

This is a way doctors measure how well the treatment is working. It refers to the percentage of patients whose tumours have either shrunk significantly or completely disappeared after 16 weeks of taking the study drug.

What are 'side effects'?

Side effects are unwanted reactions or problems that can happen from taking a medicine. The study will carefully track all side effects to understand the drug's safety profile.

Will taking part affect my regular medical care?

Participating in a study should not negatively affect your standard medical care. You can always choose to leave the study if you wish, and your doctors will continue to provide the best care for you.